EGFR and glioblastoma: They reported the successful utilization of cetuximab, an antibody targeting EGFR (overexpressed in 50-70% of GBM) conjugated to the near-infrared fluorophore IRDye800CW to effectively resect GBM tumors under fluorescence, establishing the viability and the safety of this approach.